Tim Lugo
Stock Analyst at William Blair
(0.49)
# 4,216
Out of 5,138 analysts
23
Total ratings
35.71%
Success rate
-25.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTGN Vistagen Therapeutics | Downgrades: Market Perform | n/a | $0.67 | - | 4 | Dec 17, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $55.07 | - | 3 | Oct 30, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.10 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $18.14 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $5.66 | +606.71% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $9.02 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $216.75 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $2.67 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $28.40 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $11.09 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.44 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $40.74 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.27 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.59 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $11.92 | +285.91% | 1 | May 30, 2017 |
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.67
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $55.07
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.10
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $18.14
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $5.66
Upside: +606.71%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.02
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $216.75
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.67
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $28.40
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.09
Upside: -
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.44
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $40.74
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $0.27
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.59
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $11.92
Upside: +285.91%